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The complex biology of atherosclerosis has been approached
by functional imaging from multiple directions, each exploring
the specific and distinctive etiopathogenetic mechanisms
underlying its formation and progression as well as its
subsequent complications [1–5]. In a review published
in this journal [2], the targets and the radiopharmaceuticals
with their targeting characteristics were classified into four
major groups: (1) atherosclerotic lesion components (targets
include foam cells, lipoproteins, lipids, endothelin); (2)
inflammation (targeting metabolic glucose activity, macro-
phages and monocytes, neutrophils, monocytes and lympho-
cytes, lymphocytes); (3) thrombosis (targeting platelets,
activated platelets, fibrins, etc.); and (4) apoptosis. In addition
to these aforementioned enumerated targets, there have been
recent endeavors to detect and image active arterial calcifica-
tion with 18F-fluoride positron emission tomography (PET)/CT
[6–9]. This novel approach, which requires further critical
evaluation in experimental and clinical studies, opens up the
possibility of a new armamentarium of functional imaging in
the evaluation of this complex disease process. In this
comment, we explore some demonstrated promises and take
a look at future prospects and limitations of this for being
translated into a clinical reality.
The association of aortic calcification with cardiovascular
events and all-cause mortality has been emphasized in
several reports. Inflammation and calcification are two
dynamic and complex processes that are integral components
in various pathophysiological steps of atherogenesis. Arterial
calcification has been traditionally determined by CT, whereas
inflammation mainly mediated by macrophage activity has
been assessed by 18F-fluorodeoxyglucose (FDG) PET over
the last few years. The increasing use of 18F-sodium fluoride
(NaF) PET has raised the theoretical possibility of studying
active mineral deposition in the atherosclerotic plaque perhaps
years or even decades earlier than previously.
To date there have been five clinical studies [6–10] that
have explored the feasibility of using 18F-NaF PET/CT in
assessing the calcification component of atherosclerosis.
Derlin et al., in a retrospective study [6], evaluated the
prevalence, location, and topographic relationship of
18F-NaF accumulation and vascular calcification in major
arteries. On a patient-specific analysis, 18F-NaF uptake was
observed at 254 sites in 76%, and CT calcification was
observed at 1,930 sites in 84% of the 75 study patients.
On a lesion-by-lesion analysis, colocalization of radiotracer
accumulation and CTcalcification was observed in 88% of the
PET-positive lesions, whereas only 12% of all arterial CT
calcification sites showed increased radiotracer uptake. The
investigators also observed that a higher prevalence of 18F-
NaF uptake visibility is related to a degree of calcification;
however, they found no significant correlation between the
intensity of radiotracer uptake [maximum standardized uptake
value (SUVmax)] and the calcification score [6]. Interestingly,
the per patient colocalization of 18F-NaF uptake and CT
calcification was found to be substantially higher than the
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previously reported rates of <2% and 7% concordance of 18F-
FDG and CT calcification in other studies, one of which
showed a change in the FDG uptake pattern in about half of
the patients at repeat imaging 8–26months apart with virtually
no change in CT calcifications [11–13].
In a separate study [7] by the same group of authors,
where the correlation between 18F-NaF and arterial wall
calcification in the common carotid arteries was evaluated
using a semiquantitative SUVmax technique [by placing an
individual region of interest (ROI) around the lesion on
coregistered transaxial PET/CT images], there was a signifi-
cant correlation between (a) 18F-NaF uptake and arterial wall
calcification as well as between (b) the degree of radiotracer
uptake (SUVmax) and both calcification score and calcified
lesion thickness in the atherosclerotic plaque. 18F-NaF uptake
in calcifying carotid plaque had significant correlation
with cardiovascular risk factors such as age, male sex,
hypertension, hypercholesterolemia, and cumulative smoking
exposure. The prevalence of carotid 18F-NaF accumulation
increased with the number of risk factors.
In a recently published retrospective analysis [8], where
the fluoride uptake and calcification in major arteries
(including coronary arteries) were analyzed by both
visual assessment and SUV measurement, there was
evidence of significant correlation between history of
cardiovascular events and presence of fluoride uptake
in coronary arteries. The coronary fluoride uptake value
in patients with cardiovascular events was significantly
higher than in patients without cardiovascular events.
The authors concluded that 18F-NaF PET/CT might be
useful in the evaluation of the atherosclerotic process in
major arteries, including coronary arteries, and that an
increased fluoride uptake in coronary arteries may be
associated with an increased cardiovascular risk.
In an animal study performed at the University of
Pennsylvania (unpublished data), the potential of 18F-NaF
PET/CT in detecting molecular calcification of heart and
major vessels of diabetic pigs was studied. These animals
were examined at different stages of the disease with both
18F-FDG and 18F-NaF. Interestingly, the investigators were
able to visualize molecular calcification in the heart and lower
lumbar aorta of diabetic pigs using 18F-NaF prior to visuali-
zation of any visible calcification in the CT images (Fig. 1).
In a novel study by Beheshti et al. [9], the authors
introduced a new concept for calculating global calcification
as a sensitive biomarker for detection of early molecular and
cellular calcification in the atherosclerotic plaques (Fig. 2).
The concept was primarily based upon the concept of global
disease burden, which had been earlier employed using
FDG PET in a different scenario. The feasibility of 18F-
NaF PET/CT for the quantification of global molecular
calcification of the heart and aorta was examined in this
study. Fifty-one patients with a variety of malignancies who
had undergone 18F-NaF PET/CT for skeletal evaluation
were selected for the analysis. Quantitative analysis was
performed by drawing an ellipsoid ROI on the cardiac
silhouette on each CT slice and corresponding PET slice
all over the heart. The molecular calcification score of each
particular slice was calculated by multiplying slice volume
(calculated by multiplying the area on the ROI by the slice
thickness) by the mean SUV of each ROI. The cardiac
global molecular calcification score was then obtained by
adding the molecular calcification scores among the entire
Fig. 1 Upper panel a The coronal image on 18F PET, which was
generated 1 h after the administration of 18F-NaF, reveals three sites
of uptake in the heart which likely represent calcification either in the
coronary arteries or in the soft tissues of the myocardium. b The CT
image shows no or minimal evidence of calcification at these sites. c
Fused image of PET and CT shows the location of the sites of cardiac
calcification. It is our hypothesis that calcification in the myocardium
will be detected far in advance of visualization of this pathological state
on CT images and this will have prognostic value in forecasting future
events. Lower panel a The sagittal image on 18F PET, which was
generated 1 h after the administration of 18F-NaF, reveals three sites
of uptake in the lower lumbar aorta which corresponds to sites of
calcification on the CT image (b) and their location is further confirmed
by the fused image (c). In this animal model, this is the most common site
for atherosclerosis and calcification as noted in this particular study. There
is no evidence of calcification in the descending or upper abdominal aorta
either on PET or CT images. Reproduced with permission23
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set of calculated ROIs. In this study, the authors observed
that 18F-NaF uptake in the heart and aorta increased signifi-
cantly with advancing age. Hence, they inferred from these
preliminary data that 18F-NaF PET/CTmaymake it feasible to
measure the regional and global calcification of the heart and
major arteries.
In a recently reported interesting study by Derlin et al.
[10], the macrophage activity was determined by 18F-FDG
PET and ongoing mineral deposition was measured by
18F-NaF PET in atherosclerotic plaque and these findings
were correlated with calcified plaque burden estimated by
CT. Both qualitative and semi quantitative analysis was per-
formed, and the ROIs were drawn around the visually assessed
lesions on coregistered transaxial PET/CT images manually.
The findings of this study suggested the distinctive nature of the
pathogenetic processes and hence would indicate complex
interactions between them ongoing in an atherosclerotic
plaque. Also, the investigators hypothesized that 18F-NaF
PETwould depict active mineral deposition and provide func-
tional information about the activity of the calcification process,
whereas CT could only demonstrate the presence of mere
calcification [10].
As mentioned, one of the major strengths of 18F-NaF
PET/CT is its ability to demonstrate and assess what is
assumed to be active mineral deposition in the atherosclerotic
plaque. CT calcification, on the other hand, is likely to be
influenced by both active and passive processes, the latter,
associated with necrosis, being presumed to be less important
in the study of atherosclerotic plaque, since it is frequently
observed in advanced atherosclerotic lesions [14, 15]. Inter-
estingly, thoughCTcalcification is now considered a powerful
risk marker, it does not agree very well in asymptomatic
subjects with clinical risk score algorithms like the HeartScore
[16]. In a screening study involving 1,825 individuals, CT
coronary artery calcification (CAC) was found to be common
in healthy middle-aged individuals with a low HeartScore,
and, on the contrary, high-risk subjects very frequently did not
have CAC. It is theoretically possible that 18F-NaF PET/CT
may provide highly relevant information about ongoing active
molecular calcification in the plaque which might be before
Fig. 2 Left panel This figure demonstrates a typical ROI that was
assigned to the cardiac silhouette on each CT slice and the
corresponding PET slice. As noted above, the degree of 18F-NaF
uptake is quite nonuniform throughout the selected slice and thus is
of limited value for accurate assessment of related calcification. Also,
please note that the process of uptake is diffused and does not conform
to the shape of the ventricle lumen in either ventricle. In this particular
slice the volume of the selected ROI was 30.8 cc, and the SUVmean on the
corresponding PET slice was 0.5. Therefore, the molecular calcification
score for this particular slice was calculated to be 15.4 (30.8×0.5015.4).
The global calcification score for the entire heart was calculated by adding
the individual slice values generated by this approach. Right upper panel
Relationship between cardiac global molecular calcification score
(GMCS), as measured by 18F-NaF PET/CT and age. The GMCS data
points (mean and SD) reflect 18F-NaF uptake in five different age groups
as shown above. The fitted line shows a statistically significant increase in
cardiac molecular calcification with age (Pearson correlation coefficient0
0.92; p00.003). Right lower panel Relationship between aortic SUVmean,
as measured by 18F-NaF PET/CT, and age. The aortic SUVmean data
points (mean and SD) reflect 18F-NaF uptake in five different age groups
as shown above. The fitted line shows a statistically significant increase in
aortic molecular calcification with age (Pearson correlation coefficient0
0.97; p00.004). Reproduced with permission9
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structural calcification is detectable by standard CT
techniques. Atheromatosis appears to be a lifelong process
of active and passive phases not synchronized, but at different
stages at various sites of the arterial system. Thus, it appears
reasonable to imagine increased FDG uptake signaling
macrophage infiltration as one of the very earliest signs
of active local atheromatosis and NaF accumulation as a
marker of succeeding incipient molecular calcification,
which may or may not result in overt calcification detectable
by CT. It is tempting to speculate that here could be a key to
the detection, characterization, and quantification of the active
atheromatosis process in the individual patient early enough to
allow for intervention long before symptoms may appear. The
influence of partial volume effect on the visualization of
18F-NaF uptake in the PET/CT may be considered a
limitation. However, with the development of sophisticated
techniques and software for partial volume correction and
adoption of the global molecular calcification score technique,
this limitation might be obviated in the future.
The phenomenon of atherosclerosis is a complex and
dynamic process that involves various mechanisms ongoing
at different time points of its evolution. Functional imaging
critically looking into each of these distinctive processes can
provide insight into their formation, progression, vulnerability,
and resulting atherothrombotic complications. The concept of
the vulnerable coronary plaque, i.e., the soft, lipid-filled endo-
thelial swelling with a fibrous cap that may disrupt and cause a
cascade of thromboembolic processes leading to occlusion and
acute myocardial infarction more often than narrow calcified
stenoses, has led to a search for methods that can detect these
culprit lesions in the coronary bed [2, 17]. Further, it has served
as a basis for the creation of a novel practice guideline for
cardiovascular screening in the asymptomatic at-risk
population. The main clinical purpose of noninvasive
tests for subclinical atherosclerosis in cardiovascular risk
assessment is to target intensified preventive care to
those at highest risk. Thus, in the opinion of some,
men over a certain age with certain cardiac risk factors
should be given prophylactic treatment with statins to
stabilize potential vulnerable plaques, the net result sup-
posedly being a massive reduction in coronary events
[18, 19]. However, these drugs are not without side
effects and the consequences of long-term population-
based treatment are still not known. Therefore, today’s
trend toward personalized diagnosis and therapy seems
immediately more attractive. For years it has been tried
to image coronary lesions by either single photon emission
computed tomography (SPECT) or PET. Except for a few
promising reports [20, 21], attempts to visualize the vulnerable
plaque have on the whole been disappointing due to a series of
limiting factors [1, 2, 22]. However, with the idea of measuring
global molecular cardiovascular calcification conceptually
years, perhaps decades, before it becomes macroscopically
visible, thingsmay change dramatically. Thus, activemolecular
calcification may be assessed by 18F-NaF PET/CT much
earlier than the detectable calcification identified by
CT and, hence, provide clinically relevant information
in the individual patient at an early stage when medical
intervention is likely to have correspondingly greater effect.
18F-NaF PET/CT could provide a bridging gap between the
FDG depicted inflammatory component and the CT depicted
organized calcification. Further research in this area will
hopefully generate more interesting data that will clarify
the complex interactions between the various underlying
mechanisms involved in this process in a time bound fashion.
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